Publications & Patents

Publications

2025

Comparini LM, Citi V, Ortore G, Daniele G, Sardelli F, Galgani G, Bray G, Filipponi C, De Carli A, Lai M, Nardone M, Calderone V, Falasca M, Pineschi M. Synthesis and biological evaluation of N-O heterobicyclic ring systems derived from 1,2-dihydropyridines as novel TRPA1 activators: implication in GLP-1 release and neuroprotection. Eur J Med Chem. 2025 Aug 30;300:118115. 

Malhotra P, Palanisamy R, Panda A, Casari I, Tirnitz-Parker JEE, O’Gara F, Trengove R, Ragunath K, Caparros-Martin JA, Falasca M. Cannabidiol Is Associated with Improved Survival in Pancreatic Cancer and Modulation of Bile Acids and Gut Microbiota. Int J Mol Sci. 2025 Aug 10;26(16):7733.

Thapa D, Patil M, Warne LN, Carlessi R, Falasca M. Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis. Int J Mol Sci. 2025 Aug 16;26(16):7913.

Falasca M. Special issue entitled lipids in cancer biology by Marco Falasca. Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Aug;1870(6):159653.

Nelen J, Naponelli V, Villalgordo-Soto JM, Falasca M, Pérez-Sánchez H. Targeting Drug Resistance in Cancer: Dimethoxycurcumin as a Functional Antioxidant Targeting ABCC3. Antioxidants (Basel). 2025 May 16;14(5):599.

Panda A, Ragunath K, Pajic M, Greening DW, Falasca M. Oncogenic proteome of pancreatic cancer extracellular vesicles: sodium/myo-inositol cotransporter as a potential marker. Signal Transduct Target Ther. 2025 May 7;10(1):148.

Malhotra P, Fyfe J, Emmanouilidi A, Casari I, Mellett NA, Huynh K, Pajic M, Greening DW, Meikle PJ, Falasca M. Oncogenic small extracellular vesicles enriched in sphingosine-1-phosphate play a crucial role in pancreatic cancer progression. Cell Signal. 2025 Mar 28:111775. 

Thapa D, Patil M, Warne LN, Carlessi R, Falasca M. Enhancing Tetrahydrocannabinol’s Therapeutic Efficacy in Inflammatory Bowel Disease: The Roles of Cannabidiol and the Cannabinoid 1 Receptor Allosteric Modulator ZCZ011. Pharmaceuticals (Basel). 2025 Jan 23;18(2):148.

Parham E, Ahmad M, Falasca M. Haematological Manifestations of SARS-CoV-2: Insights into Erythropoiesis, Hepcidin Regulation, and Cytokine Storm. Int J Mol Sci. 2025 Jan 21;26(3):874.

2024

Thapa D, Patil M, Warne LN, Carlessi R, Falasca M. Comprehensive Assessment of Cannabidiol and HU308 in Acute and Chronic Colitis Models: Efficacy, Safety, and Mechanistic Innovations. Cells. 2024 Dec 5;13(23):2013.

Patil M, Thapa D, Warne LN, Lareu RR, Dallerba E, Lian J, Massi M, Carlessi R, Falasca M. Chronic metabolic effects of novel gut-oriented small-molecule GPR119 agonists in diet-induced obese mice. Biomed Pharmacother. 2024 Nov 19;181:117675.

Falasca M, Manfredi M. Extracellular vesicles and biomarker discovery. Semin Cancer Biol. 2024 Sep 6;106-107:103-105.

Patil M, Casari I, Thapa D, Warne LN, Dallerba E, Massi M, Carlessi R, Falasca M. Preclinical pharmacokinetics, pharmacodynamics, and toxicity of novel small-molecule GPR119 agonists to treat type-2 diabetes and obesity. Biomed Pharmacother. 2024 Jul 4;177:117077.

Panda A, Falasca M, Ragunath K. Extracellular vesicles in pancreatic cancer: a new era in precision medicine. Transl Gastroenterol Hepatol. 2024 Apr 10;9:29. 

Vaiaki EM, Falasca M. Comparative Analysis of the Minimal information for studies of extracellular vesicles Guidelines: Advancements and Implications for Extracellular Vesicle Research. Semin Cancer Biol. 2024 Apr 22:S1044-579X(24)00033-6.

Perera CJ, Hosen SZ, Khan T, Fang H, Mekapogu AR, Xu Z, Falasca M, Chari ST, Wilson JS, Pirola R, Greening DW, Apte MV. Proteomic profiling of small extracellular vesicles derived from mouse pancreatic cancer and stellate cells: Role in pancreatic cancer. Proteomics. 2024 Apr 3:e2300067.

Palanisamy R, Indrajith Kahingalage N, Archibald D, Casari I, Falasca M. Synergistic Anticancer Activity of Plumbagin and Xanthohumol Combination on Pancreatic Cancer Models. Int J Mol Sci. 2024 Feb 16;25(4):2340.

Welsh JA, et. al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024 Feb;13(2):e12404.

Patil M, Casari I, Warne LN, Falasca M. G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype? Biomed Pharmacother. 2024 Feb 9;172:116245.

2023

Thapa D, Warne LN, Falasca M. Pharmacohistory of Cannabis Use-A New Possibility in Future Drug Development for Gastrointestinal Diseases. Int J Mol Sci. 2023 Sep 28;24(19):14677.

Fyfe J, Dye D, Razak NBA, Metharom P, Falasca M. Immune evasion on the nanoscale: Small extracellular vesicles in pancreatic ductal adenocarcinoma immunity. Semin Cancer Biol. 2023 Sep 23;96:36-47.

Fyfe J, Casari I, Manfredi M, Falasca M. Role of lipid signalling in extracellular vesicles-mediated cell-to-cell communication. Cytokine Growth Factor Rev. 2023 Oct;73:20-26.

Malhotra P, Palanisamy R, Caparros-Martin JA, Falasca M. Cancers (Basel). Bile Acids and Microbiota Interplay in Pancreatic Cancer. 2023 Jul 11;15(14):3573.

Malhotra P, Casari I, Falasca M. Can the molecules carried by extracellular vesicles help to diagnose pancreatic cancer early? Biochim Biophys Acta Gen Subj. 2023 May 24:130387.

Abu Bakar NDB, Carlessi R, Gogoi-Tiwari J, Köhn-Gaone J, Williams V, Falasca M, Olynyk JK, Ramm GA, Tirnitz-Parker JEE. TWEAK/Fn14 Signalling Regulates the Tissue Microenvironment in Chronic Pancreatitis. Cancers (Basel). 2023 Mar 16;15(6):1807.

De Giorgis V, Barberis E, Falasca M and Manfredi M. In-Depth Proteomic Analysis of Blood Circulating Small Extracellular Vesicles. Methods in Molecular Biology, 2023 2628:279-289.

Fyfe J, Malhotra P and Falasca M. Modified lipidomic profile of cancer-associated Small Extracellular Vesicles facilitates tumorigenic behaviours and contributes to disease progression. Advances in Biological Regulation, 2023 Jan; 87:100935.

2022

Selvaggi F, Melchiorre E, Casari I, Cinalli S, Cinalli M, Aceto GA, Cotellese R, Garajova I and Falasca M. Perineural Invasion in Pancreatic Ductal Adenocarcinoma: from Molecules towards Drugs of Clinical Relevance. Cancers, 2022 Nov 24; 14(23):5793.

Barberis E, Khoso S, Sica A, Falasca M, Gennari A, Dondero F, Afantitis A, Manfredi M. Precision Medicine Approaches with Metabolomics and Artificial Intelligence. Int J Mol Sci. 2022 Sep 24;23(19):11269.

Lee YT, Tan YJ, Mok PY, Kaur G, Sreenivasan S, Falasca M, Oon CE. Sex-divergent expression of cytochrome P450 and SIRTUIN 1-7 proteins in toxicity evaluation of a benzimidazole-derived epigenetic modulator in mice. Toxicol Appl Pharmacol. 2022 Jun 15;445:116039.

Falasca V, Falasca M. Targeting the Endocannabinoidome in Pancreatic Cancer. Biomolecules. 2022 Feb 17;12(2):320.

Casari I, Emmanouilidi A, Domenichini A, Falasca M. Extracellular vesicles derived from pancreatic cancer cells are enriched in the growth factor Midkine. Adv Biol Regul. 2022 Jan;83:100857.

Lian J, Casari I, Falasca M. Modulatory role of the endocannabinoidome in the pathophysiology of the gastrointestinal tract. Pharmacol Res. 2022 Jan;175:106025.

2021

Manfredi M, Williams E, Cho WC, Falasca M. Editorial: Recent Advances in In Vitro and In Vivo Multi-Omics Analyses of Extracellular Vesicles: Therapeutic Targets and Biomarkers. Front Mol Biosci. 2021 Oct 27;8:784436.

Perera CJ, Falasca M, Chari ST, Greenfield JR, Xu Z, Pirola RC, Wilson JS, Apte MV. Role of Pancreatic Stellate Cell-Derived Exosomes in Pancreatic Cancer-Related Diabetes: A Novel Hypothesis. Cancers (Basel). 2021 Oct 18;13(20):5224.

Malhotra P, Palanisamy R, Falasca M. Targeting pancreatic ductal adenocarcinoma: New therapeutic options for the ongoing battle. Hepatobiliary Pancreat Dis Int. 2022 Feb;21(1):4-

• Falasca M, Maccarrone M. Cannabinoids and Cancer. Cancers (Basel). 2021 Sep 4;13(17):4458.
• Paternoster S, Simpson PV, Kokh E, Kizilkaya HS, Rosenkilde MM, Mancera RL, Keating DJ, Massi M, Falasca M. Pharmacological and structure-activity relationship studies of oleoyl-lysophosphatidylinositol synthetic mimetics. Pharmacol Res. 2021 Aug 16;172:105822.
• Cameron K, Rozano L, Falasca M, Mancera RL. Does the SARS-CoV-2 spike protein receptor binding domain interact effectively with the DPP4 (CD26) receptor? A molecular docking study. Int J Mol Sci. 2021 Jun 29;22(13):7001.
• Casari I, Howard JA, Robless EE, Falasca M. Exosomal integrins and their influence on pancreatic cancer progression and metastasis. Cancer Lett. 2021 Jun 1;507:124-134.
• Lee XC, Werner E, Falasca M. Molecular Mechanism of Autophagy and Its Regulation by Cannabinoids in Cancer. Cancers (Basel). 2021 Mar 10;13(6):1211.
• Barberis E, Vanella VV, Falasca M, Caneapero V, Cappellano G, Raineri D, Ghirimoldi M, De Giorgis V, Puricelli C, Vaschetto R, Sainaghi PP, Bruno S, Sica A, Dianzani U, Rolla R, Chiocchetti A, Cantaluppi V, Baldanzi G, Marengo E, Manfredi M. Circulating Exosomes Are Strongly Involved in SARS-CoV-2 Infection. Front Mol Biosci. 2021 Feb 22;8:632290.
• Casari I, Manfredi M, Metharom P, Falasca M. Dissecting lipid metabolism alterations in SARS-CoV-2. Prog Lipid Res. 2021 Feb 8:101092.
• Malhotra P, Casari I, Falasca M. Therapeutic potential of cannabinoids in combination cancer therapy. Adv Biol Regul. 2021 Jan;79:100774.
• Robless EE, Howard JA, Casari I, Falasca M. Exosomal long non-coding RNAs in the diagnosis and oncogenesis of pancreatic cancer. Cancer Lett. 2021 Mar 31;501:55-65.

2020

Journal Articles (Research)

• Domenichini A, Casari I, Simpson PV, Desai NM, Chen L, Dustin C, Edmands JS, van der Vliet A, Mohammadi M, Massi M, Falasca M. Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling. J Exp Clin Cancer Res. 2020 Dec 7;39(1):276.
• Barberis E, Timo S, Amede E, Vanella VV, Puricelli C, Cappellano G, Raineri D, Cittone MG, Rizzi E, Pedrinelli AR, Vassia V, Casciaro FG, Priora S, Nerici I, Galbiati A, Hayden E, Falasca M, Vaschetto R, Sainaghi PP, Dianzani U, Rolla R, Chiocchetti A, Baldanzi G, Marengo E, Manfredi M. Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2. Int J Mol Sci. 2020 Nov 16;21(22):8623.
• Maffucci T, Falasca M. Signalling Properties of Inositol Polyphosphates. Molecules. 2020 Nov 12;25(22):5281.
• Lee YT, Tan YJ, Falasca M, Oon CE. Cancer-Associated Fibroblasts: Epigenetic Regulation and Therapeutic Intervention in Breast Cancer. Cancers (Basel). 2020 Oct 13;12(10):2949.
• Maffucci T, Falasca M. Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling. Int J Mol Sci. 2020 Sep 29;21(19):7198.
• Emmanouilidi A, Casari I, Gokcen Akkaya B, Maffucci T, Furic L, Guffanti F, Broggini M, Chen X, Maxuitenko YY, Keeton AB, Piazza GA, Linton KJ, Falasca M. Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy. Cancers (Basel). 2020 Jul 23;12(8):E2022.
• Malhotra P and Falasca M. Dual targeting of FAK and JAK/STAT3 signalling induces persistent inhibition of PDAC progression. Digestive Medicine Research 2020.
• Paternoster S, Falasca M. The Intricate Relationship between Diabetes, Obesity and Pancreatic Cancer. Biochim Biophys Acta. Reviews on Cancer 2020 Jan;1873(1):188326. doi: 10.1016/j.bbcan.2019.188326.

• Akula, S. M., S. Candido, S. L. Abrams, L. S. Steelman, K. Lertpiriyapong, L. Cocco, G. Ramazzotti, S. Ratti, M. Y. Follo, A. M. Martelli, and 12 more contributors. 2020. “Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells.“ Advances in Biological Regulation 75
• Elaskalani, O., A. Domenchini, N. B. A. Razak, D. E. Dye, M. Falasca, and P. Metharom. 2020. “Antiplatelet drug ticagrelor enhances chemotherapeutic efficacy by targeting the novel P2Y12-AKT pathway in pancreatic cancer cells.“ Cancers 12 (1)
• Caporale, C., A. M. Ranieri, S. Paternoster, C. A. Bader, M. Falasca, S. E. Plush, D. A. Brooks, S. Stagni, and M. Massi. 2020. “Photophysical and biological properties of iridium tetrazolato complexes functionalised with fatty acid chains.“ Inorganics 8 (4)

2019

Journal Articles (Research)

• Cisse O, Quraishi M, Gulluni F, Guffanti F, Mavrommati I, Suthanthirakumaran M, Oh LCR, Schlatter JN, Sarvananthan A, Broggini M, Hirsch E, Falasca M, Maffucci T. Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth. J Exp Clin Cancer Res. 2019 Nov 21;38(1):472.
• Cingolani, A., V. Zanotti, S. Zacchini, M. Massi, P. V. Simpson, N. Maheshkumar Desai, I. Casari, M. Falasca, L. Rigamonti, and R. Mazzoni. 2019. “Synthesis, reactivity and preliminary biological activity of iron(0) complexes with cyclopentadienone and amino-appended N-heterocyclic carbene ligands.“ Applied Organometallic Chemistry 33 (4)
• Domenichini, A., J. S. Edmands, A. Adamska, R. R. Begicevic, S. Paternoster, and M. Falasca. 2019. “Pancreatic cancer tumorspheres are cancer stem-like cells with increased chemoresistance and reduced metabolic potential.“ Advances in Biological Regulation 72: 63-77.
• Emmanouilidi, A., D. Paladin, D. W. Greening, and M. Falasca. 2019. “Oncogenic and Non-Malignant Pancreatic Exosome Cargo Reveal Distinct Expression of Oncogenic and Prognostic Factors Involved in Tumor Invasion and Metastasis.“ Proteomics 19 (8)
• Adamska, A., R. Ferro, R. Lattanzio, E. Capone, A. Domenichini, V. Damiani, G. Chiorino, B. G. Akkaya, K. J. Linton, V. De Laurenzi, and 2 more contributors. 2019. “ABCC3 is a novel target for the treatment of pancreatic cancer.“ Advances in Biological Regulation 73
• Emmanouilidi, A., C. A. Fyffe, R. Ferro, C. E. Edling, E. Capone, S. Sestito, S. Rapposelli, R. Lattanzio, S. Iacobelli, G. Sala, and 2 more contributors. 2019. “Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.“ Journal of Experimental and Clinical Cancer Research 38 (1)
• Adamska, A., A. Domenichini, E. Capone, V. Damiani, B. G. Akkaya, K. J. Linton, P. Di Sebastiano, X. Chen, A. B. Keeton, V. Ramirez-Alcantara, and 5 more contributors. 2019. “Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.“ Journal of Experimental and Clinical Cancer Research 38 (1)
• Lattanzio, R., M. Iezzi, G. Sala, N. Tinari, M. Falasca, S. Alberti, S. Buglioni, M. Mottolese, L. Perracchio, P. G. Natali, and 1 more contributors. 2019. “PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and-B breast cancer subtypes.“ BMC Cancer 19 (1)
• Casari, I., A. Domenichini, S. Sestito, E. Capone, G. Sala, S. Rapposelli, and M. Falasca. 2019. “Dual PDK1/aurora kinase a inhibitors reduce pancreatic cancer cell proliferation and colony formation.“ Cancers 11 (11)
• Cisse, O., M. Quraishi, F. Gulluni, F. Guffanti, I. Mavrommati, M. Suthanthirakumaran, L. C. R. Oh, J. N. Schlatter, A. Sarvananthan, M. Broggini, and 3 more contributors. 2019. “Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth.“ Journal of Experimental and Clinical Cancer Research 38 (1)

2018

Journal Articles (Research)

• Arifin, S. A., S. Paternoster, R. Carlessi, I. Casari, J. H. Ekberg, T. Maffucci, P. Newsholme, M. M. Rosenkilde, and M. Falasca. 2018. “Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119.“ Biochimica et Biophysica Acta – Molecular and Cell Biology of Lipids 1863 (9): 1132-1141.
• Abrams, S. L., K. Lertpiriyapong, L. V. Yang, A. M. Martelli, L. Cocco, S. Ratti, M. Falasca, R. M. Murata, P. L. Rosalen, P. Lombardi, and 6 more contributors. 2018. “Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.“ Advances in Biological Regulation 69: 16-34.
• Ferro, R., A. Adamska, R. Lattanzio, I. Mavrommati, C. E. Edling, S. A. Arifin, C. A. Fyffe, G. Sala, L. Sacchetto, G. Chiorino, and 5 more contributors. 2018. “GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.“ Oncogene 37 (49): 6368-6382.
• Simpson, P. V., M. Falasca, and M. Massi. 2018. “Properties and prospects for rhenium(i) tricarbonyl N-heterocyclic carbene complexes.“ Chemical Communications 54 (88): 12429-12438.

2017

Journal Articles (Research)

• Adamska, A., A. Domenichini, and M. Falasca. 2017. “Pancreatic ductal adenocarcinoma: Current and evolving therapies.“ International Journal Of Molecular Sciences 18 (7)
• Elaskalani, O., M. Falasca, N. Moran, M. C. Berndt, and P. Metharom. 2017. “The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistance.“ Cancers 9 (10): 1-19.
• Elaskalani, O., M. C. Berndt, M. Falasca, and P. Metharom. 2017. “Targeting platelets for the treatment of cancer.“ Cancers 9 (7)
• Marat, A. L., A. Wallroth, W. T. Lo, R. Müller, G. D. Norata, M. Falasca, C. Schultz, and V. Haucke. 2017. “mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate.“ Science 356 (6341): 968-972.
• Simpson, P. V., I. Casari, S. Paternoster, B. W. Skelton, M. Falasca, and M. Massi. 2017. “Defining the Anti-Cancer Activity of Tricarbonyl Rhenium Complexes: Induction of G2/M Cell Cycle Arrest and Blockade of Aurora-A Kinase Phosphorylation.“ Chemistry – A European Journal 23 (27): 6518-6521.
• Begicevic, R. R., and M. Falasca. 2017. “ABC transporters in cancer stem cells: Beyond chemoresistance.“ International Journal Of Molecular Sciences 18 (11): 1-23.
• Emmanouilidi, A., and M. Falasca. 2017. “Targeting PDK1 for chemosensitization of cancer cells.“ Cancers 9 (10)
• Emmanouilidi, A., R. Lattanzio, G. Sala, M. Piantelli, and M. Falasca. 2017. “The role of phospholipase Cγ1 in breast cancer and its clinical significance.“ Future Oncology 13 (22): 1991-1997.
• Elaskalani, O., N. B. A. Razak, M. Falasca, and P. Metharom. 2017. “Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer.“ WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY 9 (1): 37-41.
• Falasca, M., J. R. Hamilton, M. Selvadurai, K. Sundaram, A. Adamska, and P. E. Thompson. 2017. “Class II Phosphoinositide 3-Kinases as Novel Drug Targets.“ Journal Of Medicinal Chemistry 60 (1): 47-65.

2016

Journal Articles (Research)

• Chikh, A., R. Ferro, J. J. Abbott, R. Piñeiro, R. Buus, M. Iezzi, F. Ricci, D. Bergamaschi, P. Ostano, G. Chiorino, and 5 more contributors. 2016. “Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression.“ Oncotarget 7 (14): 18325-18345.
• Mavrommati, I., O. Cisse, M. Falasca, and T. Maffucci. 2016. “Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion.“ Sci Rep 6
• Arifin, S. A., and M. Falasca. 2016. “Lysophosphatidylinositol Signalling and Metabolic Diseases.“ Metabolites 6 (6)
• Falasca, M., M. Kim, and I. Casari. 2016. “Pancreatic cancer: Current research and future directions.“ Biochimica et Biophysica Acta – Reviews on Cancer 1865 (2): 123-132.
• Falasca, M., and R. Ferro. 2016. “Role of the Lysophosphatidylinositol/GPR55 axis in cancer.“ Advances in Biological Regulation 60: 88-93.
• Raimondi, C., V. Calleja, R. Ferro, A. Fantin, A. M. Riley, B. V. Potter, C. H. Brennan, T. Maffucci, B. Larijani, and M. Falasca. 2016. “A Small Molecule Inhibitor of PDK1/PLCγ1 Interaction Blocks Breast and Melanoma Cancer Cell Invasion.“ Sci Rep 6: 26142-26142.

2015

Journal Articles (Research)

• Casari, I., and M. Falasca. 2015. “Diet and Pancreatic Cancer Prevention.“ Cancers 7
• Cheung, K., L. Ma, G. Wang, D. Coe, R. Ferro, M. Falasca, C. D. Buckley, C. Mauro, and F. M. Marelli-Berg. 2015. “CD31 signals confer immune privilege to the vascular endothelium.“ Proceedings of the National Academy of Sciences 112 (43): E5815-E5824.
• Canobbio, I., L. Cipolla, G. F. Guidetti, D. Manganaro, C. Visconte, S. Kim, M. Okigaki, M. Falasca, S. P. Kunapuli, and M. Torti. 2015. “The focal adhesion kinase Pyk2 links Ca²⁺ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets.“ Biochemical Journal 469 (2): 199-210.
• Braccini, L., E. Ciraolo, C. C. Campa, A. Perino, D. L. Longo, G. Tibolla, M. Pregnolato, Y. Cao, B. Tassone, F. Damilano, and 6 more contributors. 2015. “PI3K-C2γ 3 is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling.“ Nature Communications 6: 1-15.
• Manganaro, D., A. Consonni, G. F. Guidetti, I. Canobbio, C. Visconte, S. Kim, M. Okigaki, M. Falasca, E. Hirsch, S. P. Kunapuli, and 1 more contributors. 2015. “Activation of phosphatidylinositol 3-kinase β by the platelet collagen receptors integrin α2β1 and GPVI: The role of Pyk2 and c-Cbl.“ Biochimica et Biophysica Acta – Molecular Cell Research 1853 (8): 1879-1888.
• Sestito, S., G. Nesi, S. Daniele, A. Martelli, M. Digiacomo, A. Borghini, D. Pietra, V. Calderone, A. Lapucci, M. Falasca, and 6 more contributors. 2015. “Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.“ European Journal of Medicinal Chemistry 105: 274-288.

2014

Journal Articles (Research)

• Edling, C. E., F. Selvaggi, R. Ghonaim, T. Maffucci, and M. Falasca. 2014. “Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.“ Cancer Biology and Therapy 15 (5): 524-532.
• Falasca, M., and T. Maffucci. 2014. “Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts.“ Frontiers in physiology 5
• Ruban, E. L., R. Ferro, S. A. Arifin, and M. Falasca. 2014. “Lysophosphatidylinositol: a novel link between ABC transporters and G-protein-coupled receptors.“ Biochemical Society transactions 42 (5): 1372-1377.
• Maffucci, T., and M. Falasca. 2014. “Analysis, regulation, and roles of endosomal phosphoinositides.“ Methods In Enzymology 535: 75-91.
• Falasca, M., I. Casari, and T. Maffucci. 2014. “Cancer chemoprevention with nuts.” Journal Of The National Cancer Institute 106 (9)
• Maffucci, T., and M. Falasca. 2014. “New insight into the intracellular roles of class II phosphoinositide 3-kinases.“ Biochemical Society transactions 42 (5): 1378-1382.
• Franco, I., F. Gulluni, C. C. Campa, C. Costa, J. P. Margaria, E. Ciraolo, M. Martini, D. Monteyne, E. De Luca, G. Germena, and 9 more contributors. 2014. “PI3K Class II [alpha] Controls Spatially Restricted Endosomal PtdIns3P and Rab11 Activation to Promote Primary Cilium Function.“ Developmental Cell 28 (6): 647-658.

2013

Journal Articles (Research)

• Canobbio, I., L. Cipolla, A. Consonni, S. Momi, G. Guidetti, B. Oliviero, M. Falasca, M. Okigaki, C. Balduini, P. Gresele, and 1 more contributors. 2013. “Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca2+-dependent tyrosine kinase Pyk2.“ Blood 121 (4): 648-657.
• Tibolla, G., R. Piñeiro, D. Chiozzotto, I. Mavrommati, A. P. Wheeler, G. D. Norata, A. L. Catapano, T. Maffucci, and M. Falasca. 2013. “Class II Phosphoinositide 3-Kinases Contribute to Endothelial Cells Morphogenesis.“ Plos ONE 8 (1)
• Nesi, G., S. Sestito, V. Mey, S. Ricciardi, M. Falasca, R. Danesi, A. Lapucci, M. C. Breschi, S. Fogli, and S. Rapposelli. 2013. “Synthesis of novel 3,5-disubstituted-2-oxindole derivatives as antitumor agents against human nonsmall cell lung cancer.“ ACS Medicinal Chemistry Letters 4 (12): 1137-1141.
• Fyffe, C., R. Buus, and M. Falasca. 2013. “Genetic and epigenetic regulation of phosphoinositide 3-kinase isoforms.“ Current Pharmaceutical Design 19 (4): 680-686.
• Lattanzio, R., M. Marchisio, R. La Sorda, N. Tinari, M. Falasca, S. Alberti, S. Miscia, C. Ercolani, A. Di Benedetto, L. Perracchio, and 5 more contributors. 2013. “Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy.“ International Journal Of Cancer 132 (5): 1022-1031.
• Fyffe, C., and M. Falasca. 2013. “3-phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.“ Cancer Management And Research 5 (1): 271-280.
• Lattanzio, R., M. Piantelli, and M. Falasca. 2013. “Role of phospholipase C in cell invasion and metastasis.“ Advances in Biological Regulation 53 (3): 309-318.
• Cipolla, L., A. Consonni, G. Guidetti, I. Canobbio, M. Okigaki, M. Falasca, E. Ciraolo, E. Hirsch, C. Balduini, and M. Torti. 2013. “The proline-rich tyrosine kinase Pyk2 regulates platelet integrin αIIbβ3 outside-in signaling.“ Journal Of Thrombosis And Haemostasis 11 (2): 345-356.

2012

Journal Articles (Research)

• Falasca, M., and T. Maffucci. 2012. “Regulation and cellular functions of class II phosphoinositide 3-kinases.“ Biochemical Journal 443 (3): 587-601.
• Dituri, F., A. Mazzocca, L. Lupo, C. E. Edling, A. Azzariti, S. Antonaci, M. Falasca, and G. Giannelli. 2012. “PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma.“ International Journal Of Cancer 130 (11): 2505-2513.
• Raimondi, C., and M. Falasca. 2012. “Phosphoinositides signalling in cancer: Focus on PI3K and PLC.“ Advances in Biological Regulation 52 (1): 166-182.
• Falasca, M., and K. J. Linton. 2012. “Investigational ABC transporter inhibitors.“ Expert Opinion On Investigational Drugs 21 (5): 657-666.
• Piñeiro, R., and M. Falasca. 2012. “Lysophosphatidylinositol signalling: New wine from an old bottle.“ Biochimica Et Biophysica Acta – Molecular And Cell Biology Of Lipids 1821 (4): 694-705.
• Consonni, A., L. Cipolla, G. Guidetti, I. Canobbio, E. Ciraolo, E. Hirsch, M. Falasca, M. Okigaki, C. Balduini, and M. Torti. 2012. “Role and regulation of phosphatidylinositol 3-kinase β in platelet integrin α2β1 signaling.“ Blood 119 (3): 847-856.

2011

Journal Articles (Research)

• Pĩeiro, R., T. Maffucci, and M. Falasca. 2011. “The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.“ Oncogene 30 (2): 142-152.
• Falasca, M., C. Raimondi, and T. Maffucci. 2011. “Boyden chamber.“ Methods In Molecular Biology 769: 87-95.
• Raimondi, C., and M. Falasca. 2011. “Targeting PDK1 in cancer.“ Current Medicinal Chemistry 18 (18): 2763-2769.
• Falasca, M., F. Selvaggi, R. Buus, S. Sulpizio, and C. E. Edling. 2011. “Targeting phosphoinositide 3-kinase pathways in pancreatic cancer – from molecular signalling to clinical trials.“ Anti-Cancer Agents In Medicinal Chemistry 11 (5): 455-463.
• Wu, M., M. Falasca, and E. R. Blough. 2011. “Akt/protein kinase B in skeletal muscle physiology and pathology.“ Journal Of Cellular Physiology 226 (1): 29-36.
• Dominguez, V., C. Raimondi, S. Somanath, M. Bugliani, M. K. Loder, C. E. Edling, N. Divecha, G. D. Silva-Xavier, L. Marselli, S. J. Persaud, and 5 more contributors. 2011. “Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic β cells.“ Journal Of Biological Chemistry 286 (6): 4216-4225.

2010

Journal Articles (Research)

• Falasca, M., D. Chiozzotto, H. Y. Godage, M. Mazzoletti, A. M. Riley, S. Previdi, B. V. L. Potter, M. Broggini, and T. Maffucci. 2010. “A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.“ British Journal of Cancer 102 (1): 104-114.
• Edling, C. E., F. Selvaggi, R. Buus, T. Maffucci, P. Di Sebastiano, H. Friess, P. Innocenti, H. M. Kocher, and M. Falasca. 2010. “Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.“ Clinical Cancer Research 16 (20): 4928-4937.

Conference Articles (Research)

• Abbott, J., R. Pineiro, M. A. Oliviero, R. Lattanzio, M. Piantelli, A. Bilancio, T. Maffucci, and M. Falasca. 2010. “Phosphoinositide 3-kinase class II beta is a novel target in breast cancer therapy.” In Conference on Breast Cancer Research, May 18, 2010, London, ENGLAND: BIOMED CENTRAL LTD.
• Raimondi, C., T. Maffucci, B. V. I. Potter, and M. Falasca. 2010. “A novel and selective PDK1 inhibitor reduces breast cancer cell invasion and tumour growth.” In Conference on Breast Cancer Research, May 18, 2010, London, ENGLAND: BIOMED CENTRAL LTD.
• Ruban, E., V. Martins, M. Falasca, and E. O’Toole. 2010. “Phospholipase C signalling in cutaneous squamous cell carcinoma.” In 40th Annual Meeting of the European-Society-for-Dermatological-Research (ESDR 2010), Sep 8, 2010, Helsinki, FINLAND: NATURE PUBLISHING GROUP.

2009

Journal Articles (Research)

• Falasca, M. 2009. “Anti-cancer activity of the bioactive compound inositol pentakisphosphate.“ Phytochemistry Reviews 8 (2): 369-374.
• Maffucci, T., C. Raimondi, S. Abu-Hayyeh, V. Dominguez, G. Sala, I. Zachary, and M. Falasca. 2009. “A phosphoinositide 3-kinase/phospholipase cgamma1 pathway regulates fibroblast growth factor-induced capillary tube formation.“ PLoS ONE 4 (12)

2008

Book Chapters (Research)

• Corda, D., M. Falasca, M. Di Girolamo, and T. Cacciamani. 2008. “Phospholipases in Signal Transduction.” In Biomembranes: Signal Transduction Across Membranes, 283-317

Journal Articles (Research)

• Sala, G., F. Dituri, C. Raimondi, S. Previdi, T. Maffucci, M. Mazzoletti, C. Rossi, M. Iezzi, R. Lattanzio, M. Piantelli, and 3 more contributors. 2008. “Phospholipase Cγ1 is required for metastasis development and progression.“ Cancer Research 68 (24): 10187-10196.

2007

Journal Articles (Research)

• Falasca, M., W. E. Hughes, V. Dominguez, G. Sala, F. Fostira, M. Q. Fang, R. Cazzolli, P. R. Shepherd, D. E. James, and T. Maffucci. 2007. “The role of phosphoinositide 3-kinase C2α in insulin signaling.“ Journal of Biological Chemistry 282 (38): 28226-28236.

2005

Journal Articles (Research)

• Maffucci, T., F. T. Cooke, F. M. Foster, C. J. Traer, M. J. Fry, and M. Falasca. 2005. “Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration.“ Journal of Cell Biology 169 (5): 789-799.
• Maffucci, T., E. Piccolo, A. Cumashi, M. Iezzi, A. M. Riley, A. Saiardi, H. Y. Godage, C. Rossi, M. Broggini, S. Iacobelli, and 3 more contributors. 2005. “Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.“ Cancer Research 65 (18): 8339-8349.

2004

Journal Articles (Research)

• Piccolo, E., S. Vignati, T. Maffucci, P. F. Innominato, A. M. Riley, B. V. L. Potter, P. P. Pandolfi, M. Broggini, S. Iacobelli, P. Innocenti, and 1 more contributors. 2004. “Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway.“ Oncogene 23 (9): 1754-1765.
• 2004. “40th EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004.“ Diabetologia 47 (Suppl 1): A1-A464.

Conference Articles (Research)

• Falasca, M., and T. Maffucci. 2004. “Phosphatidylinositol-3-phosphate, a new crucial player in insulin signalling, is generated via a TC10-mediated phosphoinositide 3-kinase C2alpha activation.” In 40th Annual Meeting of the European-Association-for-the-Study-of-Diabetes, Sep 5, 2004, Munich, GERMANY: SPRINGER.
• Falasca, M. 2004. “INHIBITION OF THE PI 3-K/AKT PATHWAY BY INOSITOL PENTAKISPHOSPHATE RESULTS IN PROAPOPTOTIC AND ANTI-ANGIOGENIC EFFECTS IN VITRO AND IN VIVO.”: INT INST ANTICANCER RESEARCH.

2003

Journal Articles (Research)

• Maffucci, T., A. Brancaccio, E. Piccolo, R. C. Stein, and M. Falasca. 2003. “Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation.“ EMBO Journal 22 (16): 4178-4189.
• Maffucci, T., G. Razzini, A. Ingrosso, H. Chen, S. Iacobelli, S. Sciacchitano, M. J. Quon, and M. Falasca. 2003. “Role of pleckstrin homology domain in regulating membrane targeting and metabolic function of insulin receptor substrate 3.“ Molecular Endocrinology 17 (8): 1568-1579.
• Okigaki, M., C. Davis, M. Falasca, S. Harroch, D. P. Felsenfeld, M. P. Sheetz, and J. Schlessinger. 2003. “Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration.“ Proc Natl Acad Sci U S A 100 (19): 10740-10745.

2002

Journal Articles (Research)

• Piccolo, E., P. F. Innominato, M. A. Mariggio, T. Maffucci, S. Iacobelli, and M. Falasca. 2002. “The mechanism involved in the regulation of phospholipase Cγ1 activity in cell migration.“ Oncogene 21 (42): 6520-6529.

2001

Journal Articles (Research)

• Russo, C., Y. Gao, P. Mancini, C. Vanni, M. Porotto, M. Falasca, M. R. Torrisi, Y. Zheng, and A. Eva. 2001. “Modulation of Oncogenic DBL Activity by Phosphoinositol Phosphate Binding to Pleckstrin Homology Domain.“ Journal of Biological Chemistry 276 (22): 19524-19531.

Conference Articles (Research)

• Innominato, P. F., M. A. Mariggio’, E. Piccolo, T. Maffucci, S. Iacobelli, and M. Falasca. 2001. “The mechanism involved in the regulation of PLC gamma 1 activity in cell migration.”: AMER ASSOC CANCER RESEARCH.

2000

Journal Articles (Research)

• Rodrigues, G. A., M. Falasca, Z. Zhang, S. H. Ong, and J. Schlessinger. 2000. “A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling.“ Molecular and Cellular Biology 20 (4): 1448-1459.
• Razzinit, G., A. Brancaccio, M. A. Lemmon, S. Guarnieri, and M. Falasca. 2000. “The role of the pleckstrin homology domain in membrane targeting and activation of phospholipase Cβ1.“ Journal of Biological Chemistry 275 (20): 14873-14881.
• Razzini, G., C. P. Berrie, S. Vignati, M. Broggini, G. Mascetta, A. Brancaccio, and M. Falasca. 2000. “Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.” FASEB Journal 14 (9): 1179-1187.
• Razzini, G., A. Ingrosso, A. Brancaccio, S. Sciacchitano, D. L. Esposito, and M. Falasca. 2000. “Different subcellular localization and phosphoinositides binding of insulin receptor substrate protein pleckstrin homology domains.“ Molecular Endocrinology 14 (6): 823-836.
• Berrie, C. P., and M. Falasca. 2000. “Patterns within protein/polyphosphoinositide interactions provide specific targets for therapeutic intervention.“ FASEB Journal 14 (15): 2618-2622.

1998

Journal Articles (Research)

• Falasca, M., S. K. Logan, V. P. Lehto, G. Baccante, M. A. Lemmon, and J. Schlessinger. 1998. “Activation of phospholipase Cγ by PI 3-kinase-induced PH domain-mediated membrane targeting.“ EMBO Journal 17 (2): 414-422.
• Kavran, J. M., D. E. Klein, A. Lee, M. Falasca, S. J. Isakoff, E. Y. Skolnik, and M. A. Lemmon. 1998. “Specificity and promiscuity in phosphoinositide binding by pleckstrin homology domains.“ Journal of Biological Chemistry 273 (46): 30497-30508.
• Falasca, M., C. Iurisci, A. Carvelli, A. Sacchetti, and D. Corda. 1998. “Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; A possible mechanism of autocrine control of cell proliferation.“ Oncogene 16 (18): 2357-2365.
• Wang, Y., M. Falasca, J. Schlessinger, S. Malstrom, P. Tsichlis, J. Settleman, W. Hu, B. Lim, and R. Prywes. 1998. “Activation of the c-fos serum response element by phosphatidyl inositol 3-kinase and rho pathways in HeLa cells.” Cell Growth and Differentiation 9 (7): 513-522.

1997

Journal Articles (Research)

• Logan, S. K., M. Falasca, P. Hu, and J. Schlessinger. 1997. “Phosphatidylinositol 3-kinase mediates epidermal growth factor-induced activation of the c-Jun N-terminal kinase signaling pathway.“ Molecular and Cellular Biology 17 (10): 5784-5790.
• Falasca, M., A. Carvelli, C. Iurisci, R. G. Qiu, M. H. Symons, and D. Corda. 1997. “Fast receptor-induced formation of glycerophosphoinositol-4-phosphate, a putative novel intracellular messenger in the Ras pathway.“ Molecular Biology of the Cell 8 (3): 443-453.

1996

Journal Articles (Research)

• Falasca, M., M. Marino, A. Carvelli, C. Iurisci, S. Leoni, and D. Corda. 1996. “Changes in the levels of glycerophosphoinositols during differentiation of hepatic and neuronal cells.“ European Journal of Biochemistry 241 (2): 386-392.

Conference Articles (Research)

• Corda, D., and M. Falasca. 1996. “Glycerophosphoinositols as potential markers of ras-induced transformation and novel second messengers.”
• Corda, D., and M. Falasca. 1996. “Glycerophosphoinositols as potential markers of ras-induced transformation and novel second messengers.” In Symposium on Lipid Metabolism and Function in Cancer – Significance of Magnetic Resonance Spectroscopy (MRS) Measurements in Relation to Biochemical Processes and Cellular Control, at the 5th International Conference of Anticancer Research, Oct 18, 1995, CORFU, GREECE: INT INST ANTICANCER RESEARCH.

1995

Journal Articles (Research)

• D’Arcangelo, D., M. G. Silletta, A. L. di Francesco, N. Bonfitto, A. di Cerbo, M. Falasca, and D. Corda. 1995. “Physiological concentrations of thyrotropin increase cytosolic calcium levels in primary cultures of human thyroid cells.“ Journal of Clinical Endocrinology and Metabolism 80 (4): 1136-1143.
• Falasca, M., M. G. Silletta, A. Carvelli, A. L. Di Francesco, A. Fusco, V. Ramakrishna, and D. Corda. 1995. “Signalling pathways involved in the mitogenic action of lysophosphatidylinositol.” Oncogene 10 (11): 2113-2124.

1994

Journal Articles (Research)

• FALASCA, M., and D. CORDA. 1994. “Elevated levels and mitogenic activity of lysophosphatidylinositol in k‐ras‐transformed epithelial cells.“ European Journal of Biochemistry 221 (1): 383-389.

1993

Journal Articles (Research)

• Iacovelli, L., M. Falasca, S. Valitutti, D. D’Arcangelo, and D. Corda. 1993. “Glycerophosphoinositol 4-phosphate, a putative endogenous inhibitor of adenylylcyclase.” Journal of Biological Chemistry 268 (27): 20402-20407.

1992

Journal Articles (Research)

• Gáspár, R., Z. Krasznai, T. Márián, L. Trón, R. Recchioni, M. Falasca, F. Moroni, C. Pieri, and S. Damjanovich. 1992. “Bretylium-induced voltage-gated sodium current in human lymphocytes.“ BBA – Molecular Cell Research 1137 (2): 143-147.
• Fieri, C., R. Recchioni, F. Moroni, F. Marcheselli, M. Falasca, Z. Krasznai, R. Gáspár, L. Mátyus, and S. Damjanovich. 1992. “A sodium channel opener inhibits stimulation of human peripheral blood mononuclear cells.“ Molecular Immunology 29 (4): 517-524.
• Pieri, C., F. Moroni, R. Recchioni, F. Marcheselli, M. Falasca, R. Antonicelli, and S. Damjanovich. 1992. “Aging impairs membrane potential responsiveness as well as opening of voltage and ligand gated Na⁺ channels in human lymphocytes.“ Archives of Gerontology and Geriatrics 14 (2): 145-154.
• Lupidi, G., M. Falasca, F. Marmocchi, G. Venardi, G. Cristalli, and F. Riva. 1992. “Adenosine deaminase from bovine brain: Purification and partial characterization.” Biochemistry International 26 (6): 1053-1063.
• Pieri, C., M. Falasca, F. Marcheselli, F. Moroni, R. Recchioni, F. Marmocchi, and G. Lupidi. 1992. “Food restriction in female Wistar rats: V. Lipid peroxidation and antioxidant enzymes in the liver.“ Archives of Gerontology and Geriatrics 14 (1): 93-99.
• Pieri, C., M. Falasca, F. Marcheselli, R. Recchioni, and F. Moroni. 1992. “Lipid peroxidation causes of an increase of lipid order and a decrease of 5′-nucleotidase activity in the liver plasma membrane.” Cellular and Molecular Biology 38 (4): 437-442.
• Lupidi, G., F. Marmocchi, M. Falasca, G. Venardi, G. Cristalli, M. Grifantini, E. Whitehead, and F. Riva. 1992. “Adenosine deaminase from Saccharomyces cerevisiae: kinetics and interaction with transition and ground state inhibitors.“ Biochimica et Biophysica Acta (BBA)/Protein Structure and Molecular 1122 (3): 311-316.

Conference Articles (Research)

• PIERI, C., F. MORONI, R. RECCHIONI, M. FALASCA, and F. MARCHESELLI. 1992. “Cholesterol‐Rich Rabbit Serum Modulates β‐Adrenergic Receptor Density of Human Lymphocytes: A Possible Role of LDL‐Cholesterol^a.“

1991

Journal Articles (Research)

• Pieri, C., F. Marcheselli, M. Falasca, F. Moroni, and R. Recchioni. 1991. “Food restriction in female Wistar rats, IV. Morphometric parameters of cerebellar synapses.“ Archives of Gerontology and Geriatrics 13 (2): 161-165.
• Pieri, C., M. Falasca, F. Moroni, R. Recchioni, and F. Marcheselli. 1991. “Influence of membrane fluidity on 5′-nucleotidase activity in isolated hepatocyte plasma membrane.” Biochemistry International 25 (4): 631-638.
• Pieri, C., M. Falasca, F. Moroni, R. Recchioni, and F. Marcheselli. 1991. “Diet restriction, body temperature and physicochemical properties of cell membranes.“ Archives of Gerontology and Geriatrics 12 (2-3): 179-185.
• Pieri, C., R. Recchioni, F. Moroni, M. Falasca, and S. Damjanovich. 1991. “Parameters to monitor aging with a possible perspective for intervention – an immunological approach.“ Archives of Gerontology and Geriatrics 12 (2-3): 231-238.

Conference Articles (Research)

• Pieri, C., M. Falasca, F. Moroni, F. Marcheselli, and R. Recchioni. 1991. “Studies on cell membrane properties in food restricted rats.“

1990

Journal Articles (Research)

• Pieri, C., R. Recchioni, F. Moroni, F. Marcheselli, M. Falasca, and L. Piantanelli. 1990. “Food restriction in female Wistar rats. I. survival characteristics, membrane microviscosity and proliferative response in lymphocytes.“ Archives of Gerontology and Geriatrics 11 (2): 99-108.
• Pieri, C., F. Moroni, M. Falasca, R. Recchioni, and F. Marcheselli. 1990. “Rabbit cholesterol-rich serum decreases the β-adrenergic receptor density of human lymphocytes without altering membrane microviscosity.” Medical Science Research 18 (16): 651-652.
• Pieri, C., F. Moroni, F. Marcheselli, M. Falasca, and R. Recchioni. 1990. “Food restriction in female Wistar rats. II. β-adrenoceptor density in the cerebellum and in the splenic lymphocytes.“ Archives of Gerontology and Geriatrics 11 (2): 109-115.
• Pieri, C., M. Falasca, F. Moroni, R. Recchioni, F. Marcheselli, C. Ioppolo, and F. Marmocchi. 1990. “Antioxidant enzymes in erythrocytes from old and diet restricted old rats.” Bollettino della Società italiana di biologia sperimentale 66 (10): 909-914.
• Pieri, C., M. Falasca, F. Moroni, F. Marcheselli, and R. Recchioni. 1990. “Food restriction in female Wistar rats. III. Thermotropic transition of membrane lipid and 5′-nucleotidase activity in hepatocytes.“ Archives of Gerontology and Geriatrics 11 (2): 117-124.

PATENTS

• Novel inositol phosphate derivatives. Marco Falasca, Andrew Michael Riley, Himali Yasmin Godage, Barry Victor Lloyd Potter. WO 2011064559 A3 2011

• PCT Int. Appl. (2018), WO 2018170553 A1 20180927; M. Massi, P. V. Simpson, M. Falasca: “Complexes and uses thereof”, describing the use of organometallic rhenium complexes as anticancer agents.

• PCT/AU2018/050941; P. Simpson, M. Massi, M. Falasca: “Synthetic derivatives of oleoyllysophosphatidylinositol (oleoyl-LPI) and uses thereof”, describing the use of synthetic analogues of oleyl-LPIas agonist for the GPR119 receptor.